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Knowledge base and mini-expert platform for the diagnosis
of inborn errors of metabolism
Jessica J.Y. Lee, BSc1,2,3, Wyeth W. Wasserman, PhD1,4, Georg F. Hoffmann, MD5,
Clara D.M. van Karnebeek MD, PhD1,6,7 and Nenad Blau, PhD3,5
Purpose: Recognizing individuals with inherited diseases can be
difficult because signs and symptoms often overlap those of
common medical conditions. Focusing on inborn errors of
metabolism (IEMs), we present a method that brings the knowledge
of highly specialized experts to professionals involved in early
diagnoses. We introduce IEMbase, an online expert-curated IEM
knowledge base combined with a prototype diagnosis support
(mini-expert) system.
Methods: Disease-characterizing profiles of specific bio-
chemical markers and clinical symptoms were extracted from
an expert-compiled IEM database. A mini-expert system algo-
rithm was developed using cosine similarity and semantic
similarity. The system was evaluated using 190 retrospective cases
with established diagnoses, collected from 15 different metabolic
centers.
Results: IEMbase provides 530 well-defined IEM profiles and
matches a user-provided phenotypic profile to a list of candidate
diagnoses/genes. The mini-expert system matched 62% of the
retrospective cases to the exact diagnosis and 86% of the cases to a
correct diagnosis within the top five candidates. The use of
biochemical features in IEM annotations resulted in 41% more
exact phenotype matches than clinical features alone.
Conclusion: IEMbase offers a central IEM knowledge repository
for many genetic diagnostic centers and clinical communities
seeking support in the diagnosis of IEMs.
Genet Med advance online publication 20 July 2017
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INTRODUCTION
Identification of rare genetic disorders has been greatly
improved by the advent of genome-wide sequencing. The new
technology has expanded our knowledge of rare disease
genetics and enhanced our ability to diagnose new patients.1,2
However, the diagnosis of rare genetic disorders remains a
challenge. Misdiagnoses and delayed diagnoses are often3 due
to nonspecificity and heterogeneity of signs and symptoms,
rarity of conditions, and also limited access to the knowledge
of highly specialized experts.2,4,5 Inborn errors of metabolism
(IEMs) exemplify these challenges: early signs and symptoms
are nonspecific6 and insufficiently recognized.7 For example,
in a survey of 34 junior pediatric doctors regarding their
confidence and knowledge in the acute management of three
IEMs—glutaric aciduria type I (MIM 231670), medium-chain
acyl Co-A dehydrogenase deficiency (MIM 201450), and
maple syrup urine disease (MIM 248600)—only five respon-
dents were able to identify the correct treatment steps for the
former two, while only two respondents identified the correct
steps for the latter.7 Moreover, more than 22 respondents
indicated a low level of confidence in their knowledge.7
The knowledge gap between IEM specialists and other
clinicians involved in IEM diagnoses is concerning, given
the amenability to targeted treatments for an increasing
number of IEMs; a delayed diagnosis can lead to irrever-
sible organ damage or even death. Moreover, this
disparity is widening with the explosive amount of knowledge
generated by multi-omics technology.2 Such a divide stands
in contrast to the historic efforts by the IEM clinical and
research community toward early recognition through the
creation and use of diagnostic tests, such as popu-
lation newborn screening. Thus, a potential solution may be
found in the rich disease knowledge base established by
the IEM community, dating back to Archibald Garrod’s
study on alkaptonuria in 1902.8 This compiled knowledge
base has, however, lagged behind other fields in the transi-
tion to digital form, as much of the work occurred before
modern data systems came into existence and therefore the
information was stuck on paper. Aspects have been
incorporated into large-scale rare-disease databases.9,10 How-
ever, these databases aim to provide an overview of many
kinds of individual disorders, and are not designed to guide
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clinicians in the diagnostic process. Therefore, digital transla-
tion and standardization of the IEM community knowledge
base are urgently needed to bridge the knowledge gap.
Thus, we created IEMbase, an online application that
combines the IEM community knowledge base with a
prototype mini-expert system. The expert-compiled
knowledge base provides clinical, biochemical, and genetic
profiles of 530 known IEMs. The mini-expert system accepts
a list of biochemical and clinical phenotypes from users,
compares the input phenotypic profile against IEMs in
the knowledge base using cosine similarity and semantic
similarity, and returns a list of matching IEM diagnoses.
With the resulting list, users can generate differential
diagnosis charts, biochemical test panels, and targeted
gene panels in order to pursue concurrent biochemical
and genetic/genomic investigations for a rapid diag-
nosis. IEMbase aims to renew the existing IEM com-
munity knowledge base for the modern age, creating a global
resource to facilitate the collection and dissemination
of high-quality clinical knowledge for advanced recognition
of IEMs.
MATERIALS AND METHODS
Knowledge base compilation
IEMbase was compiled by extracting 530 disease-
characterizing profiles from a nascent disease database, which
was previously compiled by more than 100 IEM experts to
produce a textbook guide on IEM classification.11 Table 1
shows an example of an extracted IEM profile. Each IEM
profile consisted of known disorder names, disorder
abbreviations, causal gene information, a MIM number,
and a list of associated biochemical markers and clinical
symptoms. Additionally, the list of biomarkers/symptoms
was annotated with information regarding onset, severity/
pathological level, and whether the biomarker/symptom is
characteristic of the associated IEM. The onset infor-
mation was organized in five categories (neonatal: birth
to 1 month, infant: 1–18 months, childhood: 1.5–11 years,
adolescence: 11–16 years, and adulthood: > 16 years).
The pathological levels of biochemical markers were
denoted by up/down/no arrows and the severities of
clinical symptoms were denoted by plus/minus signs. The
presence or absence of phenotypic characteristics was
indicated by yes/no.
The extracted profiles were manually reviewed for con-
sistency and then were imported into IEMbase as three
PostgreSQL tables, each representing the type of annotation
used in the profiles: disorders, biochemical/clinical pheno-
types, or disorder-phenotype associations (Supplementary
Figure S10 online). In total, the tables contained 530
disorders, 2,323 biochemical/clinical phenotypes, and 8,465
disorder-phenotype associations.
Additional annotations were created within each IEM
profile. One was the amenability of individual IEMs to
treatment, which was manually annotated based on previous
literature12,13 and denoted by yes/no/unknown categories.
Another was the prevalence of IEMs as reported in literature
or clinical resources.9–11,13 The last was a list of links to
relevant entries in external databases, such as UniProt,14
NCBI Gene,15 GeneCards,16 Kyoto Encyclopedia of Genes
and Genomes,17 National Institutes of Health Genetic Testing
Registry,18 and GeneReviews.19 The links were created for
interoperability with existing systems and were created using
a BioMart ID conversion tool,20 as well as URL rules specified
on the resource websites.18,19
The compiled knowledge base was assigned a version
number of 1.0.0. This initial version was used for both the
methods and the results described herein. Since the initial
compilation, IEMbase has been regularly updated with new
information. Thus, the version number has been incremented
to indicate such updates.
Mapping to structured vocabulary
A known strategy for matching user-provided phenotypic
profiles to diseases is to exploit semantic relationships
between phenotypic features, which are defined by a
structured vocabulary.21 The phenotype vocabulary in
IEMbase was not structured, but a structure could be imposed
based on a compatible external vocabulary. Therefore, the
following four standard medical vocabularies were assessed
for their compatibility with IEMbase: Human Phenotype
Ontology (HPO),22 Medical Subject Headings (MeSH),23
Systematized Nomenclature of Medicine–Clinical Terms
(SNOMED CT),24 and International Classification of
Diseases, 10th revision (ICD10).25
During compatibility assessment, HPO OBO file (2016-04-
01 release), MeSH ASCII file (2016 version), SNOMED CT
RF2 files (2016 versions), and ICD10 XML file (2016 version)
were used. The assessment proceeded in three steps. First,
unique IDs and medical terms were extracted from IEMbase
(version 1.0.0) and the four vocabularies. For SNOMED CT,
extraction was restricted to only the terms categorized under
“Clinical finding” and “Substance,” to minimize false map-
ping. The OntoCAT R package26 was used to parse HPO
terms. The standard string library and Nokogiri gem in Ruby
programming language were used to parse all others. Second,
all extracted terms were normalized using the Norm program
included in the SPECIALIST Lexical Tools.27 String normali-
zation removed the differences in alphabetic case, singular or
plural variants, punctuations, stop words, and word order.
Finally, all IEMbase terms were compared against all terms in
each vocabulary. Only the exact matches were recorded as
compatible mappings.
The initial compatibility assessment revealed that no
single vocabulary could completely cover both the bio-
chemical and the clinical phenotypes in IEMbase (Table 2).
It also revealed that the most compatible vocabulary was
different for biochemical (SNOMED CT) and clinical
phenotypes (HPO) (Table 2). Therefore, the assessment
was adjusted to consider the two phenotype categories
separately. Once adjusted, two additional biochemical
vocabularies were added: Chemical Entities of Biological
ORIGINAL RESEARCH ARTICLE LEE et al | Knowledge base of inborn errors of metabolism
152 Volume 20 | Number 1 | January 2018 | GENETICS in MEDICINE
Interest (ChEBI; OBO file; 2016-04-01 release)28 and Logical
Observation Identifiers Names and Codes (LOINC; CSV file;
version 2.56).29
Based on the adjusted assessment (Table 2), clinical pheno-
types were mapped to the most compatible vocabulary, HPO.
A medical expert manually reviewed exact matches identified
during the compatibility assessment and manually mapped
unmatched clinical phenotypes to HPO terms. In total, 1,193
of 1,200 clinical phenotypes were mapped to HPO. The
mapped HPO terms and their ancestor/descendant HPO
terms were extracted using the OntoCAT R package and were
then written into IEMbase as PostgreSQL tables. For
biochemical phenotypes, we allowed matches to terms in
any of four vocabularies: SNOMED CT, MeSH, LOINC, and
ChEBI. However, manual review of unmatched phenotypes
revealed that these terms were highly specialized and thus not
present in the vocabularies. Therefore, we implemented an
alternative strategy for assessing user-supplied biochemical
phenotypes and abandoned the established biochemical
vocabularies.
Phenotype-matching algorithm for mini-expert system
The mini-expert system of IEMbase accepts a list of
biochemical and clinical phenotypes as input. The system
then employs a two-step algorithm that compares the input
phenotypic profile against every IEM profile in IEMbase
(Figure 1).
First, the algorithm ranks IEMs by assessing only
biochemical phenotypes, using cosine similarity. Cosine
similarity30 is defined as the cosine of two vectors, TFIDFQ
and TFIDFD, which represent the input profile Q and an
IEM profile D from IEMbase. The vectors consist of term
Table 1 An example disorder profile extracted from the nascent database
Disorder name Sepiapterin reductase deficiency
Disorder abbreviation SRD
Associated gene SPR
Chromosomal localization 2p14–p12
Affected protein Sepiapterin reductase
MIM number 182125
Affected biochemical markers/clinical
symptomsa
Neonatal
(birth–1 month)
Infancy
(1–18 months)
Childhood
(1.5–11 years)
Adolescence
(11–16 years)
Adulthood
(>16 years)
Is characteristic
of disease?
Axial hypotonia ++ ++ ++ + ? No
Cerebral palsy ? ? ± ± ± Yes
Eye movements, abnormal ± ± ± ? ? No
Hypokinesia + ++ ± ± ± Yes
Muscle weakness + ± ± ± ? No
5-Hyroxyindoleacetic acid, 5HIAA
(cerebrospinal fluid)
↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ Yes
Biopterin (cerebrospinal fluid) ↑ ↑ ↑ ↑ ↑ Yes
Biopterin (urine) n n n n n No
Dihydrobiopterin (cerebrospinal fluid) ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ Yes
Homovanillic acid, HVA (cerebrospinal fluid) ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ Yes
Neopterin (cerebrospinal fluid) n n n n n No
Neopterin (urine) n n n n n No
Phenylalanine (plasma) n n n n n Yes
Prolactin (plasma) ↑ ↑ ↑ ↑ ↑ Yes
Sepiapterin (cerebrospinal fluid) ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ Yes
Sepiapterin (urine) ? ↑↑ ↑↑ ↑↑ ? Yes
For clinical symptoms, + denotes their presence and ± denotes occasional absence/presence. For biochemical markers, ↑ denotes elevated values, ↓ decreased values,
and n denotes normal values. ? denotes uncertain/unreported presence of biomarkers/symptoms.
aThe affected biochemical markers and clinical symptoms are selected for brevity.
Table 2 Vocabulary compatibility assessment results
Biochemical (no.
phenotypes
mapped)
Clinical (no.
phenotypes
mapped)
Total (no.
phenotypes
mapped)
HPO 0 450 450
ICD 10 6 92 98
SNOMED CT 371 389 760
MeSH 324 283 607
ChEBI 301 3 304
LOINC 367 61 428
ChEBI, Chemical Entities of Biological Interest; HPO, Human Phenotype Ontology;
ICD 10, International Classification of Diseases, 10th revision; LOINC, Logical
Observation Identifiers Names and Codes; MeSH, Medical Subject Headings;
SNOMED CT, Systematized Nomenclature of Medicine–Clinical Terms.
Total number of biochemical phenotypes in IEMbase is 1,123. Total number of
clinical phenotypes in IEMbase is 1,200. Total number of phenotypes in IEMbase
is 2,323.
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frequency–inverse document frequency (tfidf) scores30
defined as follows:
tf idf d; Dð Þ ¼ tf d; Dð Þ ´ idf d; Dð Þ
tf(d,D) represents the occurrence of biochemical phenotype
d in D, expressed as 0 or 1. idf(d,D) represents the specificity
of d to D, defined as:
idf d; Dð Þ ¼ logTotal number of IEMs in IEMbase
Number of IEMs associated with d
Using the above definitions, the algorithm computes tfidf
scores for all d in D and all biochemical phenotypes q in Q.
Individual tfidf scores are subsequently multiplied by a score
for matching the pathological level (i.e., elevated/normal/
decreased), which is − 1 if the levels of d and q do not match
or 1 if they match. The algorithm then computes the cosine of
vector TFIDFQ and vector TFIDFD:
cosSim TFIDFQ; TFIDFDð Þ ¼ TFIDFQ?TFIDFD8TFIDFQ88TFIDFD8
The cosine similarity scores are further multiplied by decay
factors defined based on severity/characteristics (sc) scores for
disorder D:
scDecay Dð Þ ¼ eldist
λ is a decay constant defined between 0.0 and 1.0. dist is a
Euclidean distance between a vector of sc scores for disorder
D and a vector of maximum possible sc scores. The vector of
sc scores for D consists of sc scores for individual phenotypes
d in D that match an input phenotype q in Q. The sc score for
individual d is defined as follows:
sc d; Dð Þ ¼ s d; Dð Þ ´ c d; Dð Þ
s(d,D)is the severity score of d ranging from 1 to 3, based
on the severity annotation of d. c(d,D) is the characteristic
score of d assigned either 1 or 2, based on whether d is
characteristic of D.
After the initial ranking of IEMs by biochemical pheno-
types, the algorithm breaks ties in this ranking by assessing
clinical phenotypes using semantic similarity that is computed
based on the work of Kohler et al.21 The similarity between
two clinical phenotypes, p and p′, is computed as the
information content (IC) of their most informative common
ancestor (MICAp,p′) in the HPO. IC is a measure of concrete-
ness of a phenotype p in the HPO. It is defined as:
ICðpÞ ¼ log Number of IEMs mapped to p and its descendants
Total number of IEMs in IEMbase
 
The similarity between input profile Q and an IEM profile
D is computed by averaging the best match scores for clinical
phenotypes q in Q:
semSim Q; Dð Þ ¼
Pnq
i¼1 best match score f or qi
nq
nq is the number of q in Q. The best match score for each
q is defined as IC(MICAq,dbest), where dbest is a clinical phenotype
in D whose common ancestor with q has the highest IC and the
highest severity score. The similarity score is then multiplied by
a decay factor as in biochemical similarity.
Software framework details
IEMbase data is stored in a PostgreSQL database. The front-
end user interface was developed using an Angular.js
framework. The back-end system was developed in a Ruby
on Rails framework.
Code availability
IEMbase is freely available online (http://iembase.org/app)
and upon request through an application programming
interface. Computer code used for performance evaluation
is available upon request.
Mini-expert system case study
To demonstrate a potential use case scenario of the mini-
expert system, we used a case of a delayed diagnosis of
hyperornithinemia–hyperammonemia–homocitrullinuria sy-
ndrome. Case details are described in the Results section.
Phenylalanine,
normal
Cerebral palsy
Dystonia
Hypokinesia
4. Phenylalanine,normal
User input
Biochemical
phenotype
comparison
(cosine similarity)
Clinical phenotype
comparison
(semantic similarity
and HPO)
1. Cerebral palsy 1. Sepiapterin reductase deficiency
3. GTP cyclohydrolase I deficiency
4. ...
Output
2. Dopa-responsive dystonia2. Dystonia
3. Hypokinesia
Figure 1 Mini-expert algorithm flowchart. Users enter a list of biochemical/clinical phenotypes into IEMbase’s mini-expert system. The system’s
phenotype-matching algorithm first divides the input list into biochemical and clinical categories. The algorithm then ranks the disorders in IEMbase by
comparing the biochemical profile of each disorder against the input biochemical profile, using cosine similarity. Subsequently, the algorithm breaks ties
in the ranked list by comparing the clinical profiles, using semantic similarity.
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Performance evaluation of mini-expert system
To evaluate the performance of IEMbase’s mini-expert
system, 190 retrospective cases were collected from 15
different metabolic centers. For each case, the contributors
provided the final diagnosis and biochemical/clinical infor-
mation. These cases were collected using an online form,
which restricted the contributors to providing the case
information using only the disorder and phenotype vocabul-
aries in IEMbase.
Each evaluation case was matched to potential diagnoses
using the mini-expert system. The system’s performance was
compared against three phenotype-matching algorithms, each
of which uses cosine similarity, with or without semantic
similarity, and also with or without severity and characteristic
scores.
In addition, the system performance was compared using
only biochemical phenotypes, and only clinical phenotypes of
retrospective cases. For each retrospective case, the pheno-
types were separated into biochemical and clinical categories
before each category was evaluated with the mini-expert
system. Eighteen cases with phenotypes only in either category,
were excluded from this paired comparison (n = 172).
We also tested whether the number of phenotypes specified
for each case correlated with the rank of correct diagnoses, in
order to assess if some cases ranked better than others because
more phenotypes were provided for them.
The above evaluations were conducted using version 1.0.0
of IEMbase. Difference in performance was statistically tested
using the Mann-Whitney-U test implemented by wilcox.test
in R (version 3.3.1). The correlation test was performed using
Spearman’s rank correlation test, implemented by cor.test in
R. All plots were generated using the ggplot2 R package.
RESULTS
Overview and walkthrough of IEMbase
We developed IEMbase as an online application which
combines a comprehensive IEM knowledge base with a diag-
nosis support (mini-expert) system. IEMbase curates expert-
provided information on 530 IEMs, their treatability and
genetics, as well as associated biochemical/clinical phenotypes
with detailed annotations on the onset/severity/pathological
level of the phenotypes. The application is freely available and
can be accessed at http://www.iembase.org/app, or from a link
on the project overview website (http://www.iembase.org).
IEMbase is also available through an application-program-
ming interface for integration into other computational
systems. Application-programming interface access is avail-
able upon request.
A detailed walkthrough of the application is presented in
the Supplementary Materials and Methods.
Applying mini-expert system in clinical settings
We demonstrate the utility of IEMbase’s mini-expert system
using a case of a delayed hyperornithinemia–hyperammone-
mia–homocitrullinuria (HHH) syndrome diagnosis. A girl 2
years and 8 months of age had shown inconspicuous
psychomotor development. Following an upper respiratory
tract infection, she developed recurrent vomiting, while
refusing feeding but drinking occasionally. She was slightly
lethargic. Over the following weeks she never fully recovered
and continued to undergo episodes of postprandial vomiting,
lethargy, and apparent seizures reminiscent of absences.
Laboratory tests revealed hyperammonemia (260 μmol/L)
together with the constellation of acute liver failure (ASAT
130 U/l, ALAT 233 U/l, ALP 267 U/l, Quick 10%, INR 4.87,
aPTT 52 sec.). Plasma amino acids demonstrated high to
normal glutamine, elevated ornithine, and low citrulline and
arginine, all as abnormalities. Orotic acid was highly elevated
in urine. Homocitrulline was specifically tested for but could
not be identified in plasma or urine. With a presumptive
diagnosis of ornithine transcarbamylase deficiency, the patient
was referred to a metabolic center and treated, accordingly,
with protein restriction and ammonia scavengers. Over the
following months, there were several similar episodes, usually
triggered by minor intercurrent infections. Molecular analysis
of ornithine transcarbamylase was negative.
When the constellation of symptoms was entered into the
IEMbase’s mini-expert system (Supplementary Table S1),
hyperornithinemia–hyperammonemia–homocitrullinuria syn-
drome was suggested as the most likely disease candidate,
while ornithine transcarbamylase deficiency was listed as the
second probable disease candidate. Indeed, molecular analysis of
SLC25A15 identified biallelic variants in the gene, confirm-
ing the diagnosis of hyperornithinemia–hyperammonemia–
homocitrullinuria syndrome and enabling targeted treatment.
Mini-expert system performance evaluation
IEMbase’s mini-expert system matched 62% of cases to exact
diagnoses, 86% of cases within the top five candidate
disorders, and 90% of cases within the top ten. The perfor-
mance comparison between the mini-expert system algorithm
(combined + weighted) and three other phenotype-matching
algorithms (combined + unweighted, cosine + weighted,
cosine + unweighted) is shown in Table 3 and Supplemen-
tary Figure S11. There was no significant difference in
performance between the mini-expert algorithm and the
alternative phenotype-matching algorithms. Cases that were
ranked out of the top 20 tended to have entries of unspecific
biochemical markers, such as “Acylcarnitines, all” or “Amino
acids, all.” Refer to Supplementary Table S2 for an overview
of the cases and their ranks. Refer to Supplementary Table S3
for more information about the cases that were ranked out of
the top 20.
The system performance using only biochemical queries
was significantly better than using only clinical queries
(Po 2.2e-16; Figure 2 and Supplementary Table S4). Using
only biochemical phenotypes, 60% of cases were matched to
exact diagnoses, 83% of cases within the top five candidate
disorders, and 89% of cases within the top ten. The success
rate of biochemical phenotypes plateaued after 90%, as the
number of assessed candidates increased, reflecting 13 cases
which failed to produce candidates owing to insufficient/
Knowledge base of inborn errors of metabolism | LEE et al ORIGINAL RESEARCH ARTICLE
GENETICS in MEDICINE | Volume 20 | Number 1 | January 2018 155
unspecific biochemical information and/or the system’s
inability to recognize similar biochemical phenotypes. As an
example of the latter, the current implementation fails to
recognize “Acylcarnitines, all” and “Long-chain acylcarnitine”
as related phenotypes. Using only clinical phenotypes, only
19% of cases were matched to exact diagnoses, 38% of cases
within the top five candidate disorders, and 49% of cases
within the top ten.
There was no significant correlation between the rank of
correct diagnoses and the number of provided phenotypes
(P = 0.69; Supplementary Figure S12).
DISCUSSION
Although disease databases for IEMs have been developed in
the past,31–33 they were either based on individual case
reports31,32 or more focused on specific symptoms, such as
intellectual disability.33 Large-scale rare disease databases
currently available for a general clinical audience9,10 do cover
a wide range of rare diseases, but by their nature do not
provide the depth of information found in specialized expert
knowledge bases. IEMbase is designed to fill this gap, by
combining a central knowledge repository with a basic
diagnostic support system. This design allows simultaneous
collection of the current expert knowledge and its dissemina-
tion to the broader clinical community. In addition, it leads to
further improvement of the mini-expert system as the depth
of knowledge is compiled. Curated knowledge bases are
intended to surpass the capacity of any single expert. IEMbase
is therefore of utility for all those involved in IEM diagnoses:
pediatricians, internists, neurologists, geneticists, and meta-
bolic specialists. As our case study demonstrates, the utility of
IEMbase can also be extended to established metabolic centers
and biochemical genetics laboratories to help broaden the
array of potential differential diagnoses—specifically to
include lesser-known diseases when their constellations
overlap with typical presentations of better-known diseases.
The evaluation of the mini-expert system revealed that
phenotype-matching performance is significantly higher with
the use of biochemical phenotypes than that of clinical
phenotypes. This probably reflects two influences: (i) many
clinical features of IEMs are not specific, while biochemical
alterations are frequently so6,34 and (ii) the IEM community
has made intense efforts toward both disease-specific
biomarker discovery and the annotation of biochemical
phenotypes.11,12,34,35 The second point draws upon a hundred
years of IEM community efforts, leading to a depth and
breadth of biochemical annotations that constitute a phenome
space well suited to research of assisted diagnostic methods.
Furthermore, the uniting of biochemical annotations with
genetic and clinical annotations aligns with the imminent
shift in investigative paradigm, where multi-omics technology
allows holistic investigation into an individual’s genome,
epigenome, transcriptome, proteome, metabolome, and
phenome.34 Extrapolating from our experience, the knowl-
edge bases of other clinical communities may hold untapped
high-quality offline information which could be renewed in a
similar way to that held in IEMbase.
Owing to a lack of compatible structured vocabulary for
biochemical phenotypes in IEMbase, the current mini-expert
Table 3 Mini-expert system performance evaluation results
Combined +weighted (mini-expert system) Combined + unweighted Cosine +weighted Cosine + unweighted
MRR 0.72 0.70 0.72 0.68
% success at 1 62 59 63 57
% success at 5 86 85 85 83
% success at 10 90 91 90 89
% success at 20 93 92 92 91
Mean reciprocal rank (MRR) measures how close the correct match is to the top rank on average. It ranges from 0 to 1, and values close to 1 indicate that correct mat-
ches appear closer to the top on average. % success at N = % of cases with correct diagnoses within top N ranks. Combined = combined cosine and semantic similar-
ity. Cosine = cosine similarity only.
100
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Top N ranks
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Figure 2 Mini-expert system performance using only biochemical/
clinical information. The system performance when using only
biochemical phenotypes was compared with that when using only clinical
phenotypes of 172 retrospective cases. Percentage success N measures %
of cases whose actual diagnoses ranked within the top N ranks. The
system performance when using only biochemical phenotypes was
significantly better than that when using only clinical phenotypes
(Po 2.2e-16; Mann-Whitney-U).
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system algorithm uses a nonsemantic information retrieval
metric (tfidf-cosine similarity) to compare biochemical
phenotypes. We recognize that this approach is not robust
when matching imprecise terms. For example, the use of tfidf-
cosine similarity will not take into account the fact that
neopterin and biopterin belong to the same group of pterins.
The use of structured vocabulary and semantic similarity can
mitigate this shortcoming. Therefore, we plan to contribute
our biochemical vocabulary to existing ontologies as we make
updates to our system.
Biochemical test/gene panel suggestions that are provided
with the output of the mini-expert system are currently
restricted to basic information (e.g., gene names or chemical
test panels), as detailed specification will require future
contributions from the expert community. We anticipate that
such improvements will be introduced over time as a result of
community outreach efforts such as those described below.
For the long-term viability of IEMbase, continuous
contribution from the expert community is crucial, especially
with the large number of novel IEMs and phenotypes now
being revealed with the use of multi-omics technologies.
Therefore, we will periodically reach out to the IEM
community for knowledge contribution, in addition to
assembling an expert panel, which will regularly review and
update the knowledge base. To encourage adoption among
the new generation of clinicians, we plan to develop a mobile
version of the application and a training module.
In summary, IEMbase is a web application intended to
provide the clinical community with a comprehensive IEM
knowledge base and a tool to facilitate early and accurate
diagnoses of IEMs. Its knowledge base features expert-curated
clinical resources on 530 IEMs. Its mini-expert system
empowers clinicians and complements their workflow with
suggested diagnoses, differential diagnosis charts, biochemical
test panels, and gene panels. The multitude of suggestions
enables clinicians to initiate concurrent biochemical and
genetic evaluations, where the former can help focus the latter
for rapid diagnosis, especially in clinical exome/genome
interpretations. We believe that the power of IEMbase comes
from the community of experts who contribute their knowl-
edge for the greater benefit of the broader clinical community
and as such, the value of community science should be
recognized as a key component of digital medicine in the 21st
century.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the
paper at http://www.nature.com/gim
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